Evidence map›Paper›PMID 41893323›Full record

ArticleMetabolites2026

Metabolomic Study of 7-Ethyl-9-(

Piotr Surynt, Beata Naumczuk, Magdalena Popławska, Magdalena Urbanowicz, Katarzyna Unrug-Bielawska, Magdalena Cybulska-Lubak, Zuzanna Sadowska-Markiewicz, Jerzy Sitkowski, Elżbieta Bednarek, Natalia Zeber-Lubecka and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Piotr SuryntDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
Beata NaumczukLaboratory for Analysis of Bioactive Compounds, Institute of Organic Chemistry Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland.ORCID 0000-0003-3740-8387
Magdalena PopławskaFalsified Medicines and Medical Devices Department, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.
Magdalena UrbanowiczFalsified Medicines and Medical Devices Department, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.ORCID 0000-0001-7976-633X
Katarzyna Unrug-BielawskaDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.ORCID 0000-0003-3453-1590
Magdalena Cybulska-LubakDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
Zuzanna Sadowska-MarkiewiczDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
Jerzy SitkowskiFalsified Medicines and Medical Devices Department, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.ORCID 0000-0002-9962-6024
Elżbieta BednarekFalsified Medicines and Medical Devices Department, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.ORCID 0000-0002-1275-8893
Natalia Zeber-LubeckaDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
Lech KozerskiFalsified Medicines and Medical Devices Department, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.
Michał MikulaDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.ORCID 0000-0003-3447-7328
Jerzy OstrowskiDepartment of Genetics, Maria Skłodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.

Funding

National Science Centre 2018/31/B/NZ7/02675
6 · The paper itself

Abstract

backgroundIn this study, we aimed to compare metabolomic profiles, biodistribution, and detoxification patterns of the novel SN-38 derivative NMe with irinotecan (IR), and to identify NMe-specific metabolites to evaluate its preclinical pharmacokinetic advantages.

methodsIn vivo ADME studies were conducted for NMe, a 9-aminomethyl SN-38 derivative, and IR following a single intraperitoneal dose of 40 mg/kg in mice. Additionally, ADMET properties were predicted using ADMETlab and SwissADME tools for comparison. Levels of NMe and irinotecan absorbed into plasma, distributed to tissues, and metabolized were monitored in liver, lung, spleen, kidney, and stool samples at 15, 30, and 60 min post-administration. Tissue extracts were analysed using high-performance liquid chromatography (HPLC), liquid chromatography-electrospray ionization quadrupole time-of-flight-tandem mass spectrometry (LC-ESI-QTOF-MS), and nuclear magnetic resonance (NMR) techniques after lyophilization and reconstitution. We compared the metabolomic profiles of irinotecan and NMe.

resultsWe identified and confirmed NMe-specific metabolites, including 9-CH

conclusionsNMe shows a distinct metabolic profile characterized by rapid biotransformation, higher systemic glucuronidation of SN-38, and formation of unique metabolites, suggesting a potentially wider therapeutic window and reduced toxicity compared with IR.

Indexed as

ADME studycomparative studyhigh-resolution mass spectrometry (HRMS)irinotecanmetabolitesmetabolomic studyNMerenal excretiontandem mass spectrometrytissue distribution

Identifiers

PMID41893323
PMCPMC13027767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.